CXBS (Corix Bioscience) Total Liabilities: $0.79 Mil (As of Sep. 2017)


What is Corix Bioscience Total Liabilities?

Corix Bioscience CXBS -99.00% Total Liabilities is $0.79 Mil as of Sep. 2017.

Corix Bioscience's Total Liabilities for the quarter that ended in Sep. 2017 was $0.79 Mil.

Corix Bioscience's quarterly Total Liabilities increased from Mar. 2017 ($0.00 Mil) to Jun. 2017 ($3.96 Mil) but then declined from Jun. 2017 ($3.96 Mil) to Sep. 2017 ($0.79 Mil).

Corix Bioscience's annual Total Liabilities declined from Jan. 2014 ($0.02 Mil) to Jan. 2015 ($0.00 Mil) but then increased from Jan. 2015 ($0.00 Mil) to Dec. 2016 ($5.76 Mil).

Corix Bioscience Total Liabilities Historical Data

* Premium members only.

The historical data trend for Corix Bioscience's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corix Bioscience Total Liabilities Chart

Corix Bioscience Annual Data
Trend Jan09 Jan10 Jan11 Jan12 Jan13 Jan14 Jan15 Dec16
Total Liabilities
Get a 7-Day Free Trial 0.01 0.02 0.02 0.00 5.76

Corix Bioscience Quarterly Data
Oct12 Jan13 Apr13 Jul13 Oct13 Jan14 Apr14 Jul14 Oct14 Jan15 Apr15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.01 5.76 0.00 3.96 0.79

Corix Bioscience Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Corix Bioscience's Total Liabilities for the fiscal year that ended in Dec. 2016 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.687+(5.077+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=5.76

Total Liabilities=Total Assets (A: Dec. 2016 )-Total Equity (A: Dec. 2016 )
=11.37-5.606
=5.76

Corix Bioscience's Total Liabilities for the quarter that ended in Sep. 2017 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.786+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=0.79

Total Liabilities=Total Assets (Q: Sep. 2017 )-Total Equity (Q: Sep. 2017 )
=4.344-3.558
=0.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $0.79 Mil mean?
Corix Bioscience (CXBS) has a Total Liabilities of $0.79 Mil as of Sep. 2017. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Corix Bioscience and its competitors.
Is Corix Bioscience's Total Liabilities too high?
Corix Bioscience's current Total Liabilities is $0.79 Mil.
How does Corix Bioscience's Total Liabilities compare to BKIT and YBAO?
Corix Bioscience's Total Liabilities of $0.79 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Corix Bioscience and its competitors. Corix Bioscience's current Total Liabilities is $0.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corix Bioscience stock overvalued right now?
Corix Bioscience (CXBS) has a current Total Liabilities of $0.79 Mil. The current Total Liabilities is $0.79 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Corix Bioscience (CXBS), the current Total Liabilities is $0.79 Mil as of Sep. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corix Bioscience Business Description

Address 18662 MaCaurther Boulevard, Suite 200, Irvine, CA, USA, 85085
Corix Bioscience Inc is a United States-based research and development firm of cannabidiol (CBD) products and treatments. It is engaged in the business of producing organic CBD oil used for medical applications and treatments. In addition, the group is also focused on the production of tetrahydrocannabivarin oil. The company is focused on operations in Oregon, California, and Nevada, United States.